| Literature DB >> 34552825 |
Bhuwan Giri1, Prateek Sharma2, Tejeshwar Jain2, Anthony Ferrantella1, Utpreksha Vaish2, Siddharth Mehra1, Bharti Garg1, Srikanth Iyer2, Vrishketan Sethi2, Zoe Malchiodi1, Rossana Signorelli1, Harrys K C Jacob1, John George1, Preeti Sahay2, Ejas P Bava2, Rajinder Dawra1, Sundaram Ramakrishnan1, Ashok Saluja1, Vikas Dudeja2.
Abstract
Heat shock protein 70 (Hsp70), a protein chaperone, is known to promote cell survival and tumor progression. However, its role in the tumor microenvironment (TME) is largely unknown. We specifically evaluated Hsp70 in the TME by implanting tumors in wild-type (WT) controls or Hsp70-/- animals, thus creating a TME with or without Hsp70. Loss of Hsp70 led to significantly smaller tumors; there were no differences in stromal markers, but interestingly, depletion of CD8 + T-cells abrogated this tumor suppressive effect, indicating that loss of Hsp70 in the TME affects tumor growth through the immune cells. Compared to WT, adoptive transfer of Hsp70-/- splenocytes exhibited greater antitumor activity in immunodeficient NSG and Rag 1-/- mice. Hsp70-/- dendritic cells showed increased expression of MHCII and TNF-α both in vitro and in vivo. These results suggest that the absence of Hsp70 in the TME inhibits tumors through increased dendritic cell activation. Hsp70 inhibition in DCs may emerge as a novel therapeutic strategy against pancreatic cancer.Entities:
Keywords: Hsp70; Pancreatic cancer; dendritic cells; immunotherapy; stroma
Mesh:
Substances:
Year: 2021 PMID: 34552825 PMCID: PMC8451449 DOI: 10.1080/2162402X.2021.1976952
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110